- Published at
- by seekingalpha.com
positive
positive
Syndax Pharmaceuticals: Down But Not Out (NASDAQ:SNDX)
Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my recommendation for SNDX.
News for Syndax Pharmaceuticals, Inc. (SNDX)
- Published at
- by gurufocus.com
neutralneutralSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals ( SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
neutralneutral- Published at
- by gurufocus.com
neutralneutralQ4 2024 Syndax Pharmaceuticals Inc Earnings Call Transcript
Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NSNDX.OQ - Syndax Pharmaceuticals IncQ4 2024 Syndax Pharmaceuticals Inc Earnings CallMar 03, 20- Published at
- by gurufocus.com
neutralneutralDecoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Insight
Strengths: Innovative cancer therapies and robust clinical pipeline.Weaknesses: Limited experience in generating revenue from product sales.Opportunities: Expa- Published at
- by seekingalpha.com
positivepositiveSyndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ETCompany ParticipantsSharon Klahre - Head of IRMichael...- Published at
- by seekingalpha.com
neutralneutralSyndax Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call Presentation (NASDAQ:SNDX)
The following slide deck was published by Syndax Pharmaceuticals, Inc.- Published at
- by zacks.com
negativenegativeSyndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of -1.85% and 65.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?- Published at
- by gurufocus.com
positivepositiveSyndax Pharmaceuticals Inc (SNDX) Reports Strong Initial Sales and Strategic Developments
Syndax Pharmaceuticals Inc (SNDX), a commercial-stage biopharmaceutical company, announced its financial results for the fourth quarter and full year ending Dec- Published at
- by gurufocus.com
neutralneutralSyndax Pharmaceuticals Reports Q4 2024 EPS of -$1.10, Missing Estimates; Revenue at $7.7 Million
Revenue: Achieved $7.7 million in net product revenue for Revuforj in the initial five weeks of its U.S. launch.EPS: Reported a net loss per share of $1.10, mi- Published at
- by seekingalpha.com
negativenegativeSyndax Pharmaceuticals misses Q4 estimates; initiates Q1 and FY25 outlook (NASDAQ:SNDX)
Syndax Pharmaceuticals press release (SNDX): Q4 GAAP EPS of -$1.10 misses by $0.28. Revenue of $7.68M misses by $78.83M. Financial Guidance For the first quarter of 2025, the company- Published at
- by seekingalpha.com
neutralneutralSyndax Pharmaceuticals Q4 2024 Earnings Preview (NASDAQ:SNDX)
Syndax Pharmaceuticals (SNDX) to report Q4 earnings on March 3. Explore EPS growth, revenue forecasts, and recent estimate revisions.- Published at
- by gurufocus.com
positivepositiveEarnings To Watch: Syndax Pharmaceuticals Inc (SNDX) Reports Q4 2024 Result
Syndax Pharmaceuticals Inc (SNDX) is set to release its Q4 2024 earnings on Mar 3, 2025. The consensus estimate for Q4 2024 revenue is $85.91 million, and the e- Published at
- by gurufocus.com
positivepositiveSyndax Pharmaceuticals Inc (SNDX) Announces Upcoming Financial Results and Business Update
Syndax Pharmaceuticals Inc (SNDX), a commercial-stage biopharmaceutical company focused on developing innovative cancer therapies, has announced that it will re- Published at
- by manilatimes.net
negativenegative- Published at
- by gurufocus.com
negativenegativeSyndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals ( SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeli- Published at
- by gurufocus.com
positivepositiveKynam Capital Management, LP Increases Stake in Syndax Pharmaceuticals Inc.
On December 31, 2024, Kynam Capital Management, LP (Trades, Portfolio) executed a significant transaction by acquiring an additional 2,677,075 shares of Syndax- Published at
- by gurufocus.com
positivepositiveKynam Capital Management, LP Increases Stake in enGene Holdings Inc
On December 31, 2024, Kynam Capital Management, LP (Trades, Portfolio) made a significant move by acquiring an additional 3,257,863 shares of enGene Holdings In- Published at
- by gurufocus.com
positivepositiveKynam Capital Management, LP Reduces Stake in Dynavax Technologies Corp
On December 31, 2024, Kynam Capital Management, LP (Trades, Portfolio) executed a significant transaction involving the reduction of its holdings in Dynavax Tec